GH Options (GH20260220C110) Price & Quote

Symbols

--(--)

Expected P&L on Expiry

Key Stats

0.00DAY`S RANGE0.00

Open

0.00

Prev.Close

0.00

Turnover

Volume

Premium

Extrinsic Value

Open Interest

Intrinsic Value

Pricing Model

Delta

Gamma

Theta

Vega

Rho

Theor Price

About GH20260220C110

Underlying

Guardant Health, Inc.

Industry

Biological Technology

Introduction

Guardant Health, Inc., was incorporated in Delaware in December 2011. The company is a leading precision oncology company dedicated to helping the world conquer cancer through the use of its proprietary blood tests, extensive datasets and advanced analysis. Guardant Health, Inc., believes that the key to conquering cancer is unprecedented access to its molecular information at all stages of the disease, which they intend to achieve through routine blood draws or liquid biopsies. Guardant Health Guardant Health Oncology Platform aims to leverage its capabilities in technology, clinical development, regulation and reimbursement to drive commercial applications, improve patient clinical outcomes and reduce healthcare costs. In order to achieve their goal of managing cancer at all stages of the disease, the company has launched their liquid biopsy tests, Guardant 360 and Guardant OMNI, for the treatment of advanced cancer, to power the company's program of recurrence and early detection testing, LUNAR-1 and LUNAR-2, respectively.